Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Public ClinicalTrials.gov record NCT05067127. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN) on the basis of a reduction in proteinuria.
Study identification
- NCT ID
- NCT05067127
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 124 participants
Conditions and interventions
Conditions
- C3G
- IC-MPGN
- C3 Glomerulopathy
- C3 Glomerulonephritis
- Complement 3 Glomerulopathy
- Complement 3 Glomerulopathy (C3G)
- Complement 3 Glomerulonephritis
- Dense Deposit Disease
- DDD
- Membranoproliferative Glomerulonephritis
- Membranoproliferative Glomerulonephritis (MPGN)
- Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 12, 2021 (Actual)
- Primary completion
- Jun 26, 2024 (Actual)
- Completion
- Jan 14, 2025 (Actual)
- Last update posted
- Jan 29, 2026
2021 – 2025
United States locations
- U.S. sites
- 26
- U.S. states
- 17
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| Academic Medical Research Institute | Los Angeles | California | 90022 | — |
| Keck School of Medicine, University of Southern California | Los Angeles | California | 90033 | — |
| Ronald Reagan UCLA Medical Center (01035) | Los Angeles | California | 90095 | — |
| UCI Center for Clinical Research | Orange | California | 92868 | — |
| UC Davis Medical Center (Transplant Research) (01016) | Sacramento | California | 95817 | — |
| Children's Hospital Colorado | Aurora | Colorado | 80045 | — |
| University of Florida | Gainesville | Florida | 32610 | — |
| Emory University School of Medicine | Atlanta | Georgia | 30322 | — |
| Fides Clinical Research, LLC (01042) | Atlanta | Georgia | 30342 | — |
| Institute for Public Health and Medicine Northwestern University Northwestern University (01041) | Chicago | Illinois | 60611 | — |
| NANIU Research Chicago (01040) | Oak Brook | Illinois | 60523 | — |
| Nephrology Associates of Northern IL and Inn (01043) | Fort Wayne | Indiana | 46804 | — |
| The University of Iowa | Iowa City | Iowa | 52242 | — |
| Boston Children's Hospital (01013) | Boston | Massachusetts | 02115 | — |
| Renal and Transplant Associates of New England, PC | Springfield | Massachusetts | 01107 | — |
| University of Michigan Medical Center | Ann Arbor | Michigan | 48109 | — |
| Children's Mercy Hospital | Kansas City | Missouri | 64102 | — |
| Hackensack Meridian Health | Hackensack | New Jersey | 07601 | — |
| Cohen Children Hospital | New Hyde Park | New York | 11040 | — |
| CUIMC - Columbia Nephrology | New York | New York | 10032 | — |
| The Ohio State University Medical Center | Columbus | Ohio | 43210 | — |
| Oregon Health & Science University (01038) | Portland | Oregon | 97239 | — |
| Northeast Clinical Research Center, LLC | Bethlehem | Pennsylvania | 18017 | — |
| MedResearch Inc | El Paso | Texas | 79902 | — |
| Texas Children's Hospital | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 99 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05067127, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 29, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05067127 live on ClinicalTrials.gov.